Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder

  • Authors:
    • Kazuhiro Kataoka
    • Yutaka Kono
    • Masanobu Sugimoto
    • Yasuhiro Furuichi
    • Masayoshi Shichiri
    • Yujiro Tanaka
  • View Affiliations

  • Published online on: September 29, 2010     https://doi.org/10.3892/etm.2010.159
  • Pages: 1041-1047
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rifampicin (RFP) is a semisynthetic antibiotic derived from the rifamycins and is one of the most commonly used pharmaceutical compounds worldwide in the treatment of tuberculosis. We previously reported that low-dose and long-term oral administration of RFP to 6 hepatitis C virus-related liver cirrhosis patients who were at high risk for presenting with hepatocellular carcinoma (HCC) resulted in a marked suppression of the occurrence of HCC without showing an adverse effect. The underlying mechanism was found to be due to the anticancer effect based on the potent anti-angiogenic properties of RFP. The present study revealed that RFP has an additional hepatocyte-protective effect by lowering the release of hepatic enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in chronic hepatitis C patients. Experimentally, we were able to show that RFP had hepatocyte-protective effects in acute hepatocyte disorder models of mice and rats induced by concanavalin A and by D-galactosamine, respectively: RFP significantly prevented an increase in the levels of ALT, AST and lactate dehydrogenase in these animal models. In addition, we found that RFP had a strong anti-oxidant action which was approximately three times stronger than the action of silibinin, an anti-inflammatory agent of human hepatic stellate cells, implicating that the hepatocyte-protective effects of RFP are mediated by its anti-oxidant activity. These results reveal that oral administration of RFP exerts not only a prophylactic effect on the occurrence or recurrence of HCC for an extensive period of time, but also exerts hepatocyte-protective effects on both human chronic hepatitis C and acute hepatocyte disorder in rodent models, and the anti-oxidant activity of RFP is implicated to participate in the latter effects.
View Figures
View References

Related Articles

Journal Cover

October 2010
Volume 1 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Kataoka, K., Kono, Y., Sugimoto, M., Furuichi, Y., Shichiri, M., & Tanaka, Y. (2010). Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder. Experimental and Therapeutic Medicine, 1, 1041-1047. https://doi.org/10.3892/etm.2010.159
MLA
Kataoka, K., Kono, Y., Sugimoto, M., Furuichi, Y., Shichiri, M., Tanaka, Y."Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder". Experimental and Therapeutic Medicine 1.6 (2010): 1041-1047.
Chicago
Kataoka, K., Kono, Y., Sugimoto, M., Furuichi, Y., Shichiri, M., Tanaka, Y."Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder". Experimental and Therapeutic Medicine 1, no. 6 (2010): 1041-1047. https://doi.org/10.3892/etm.2010.159